{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zettlitz KA"],"funding":["NCI NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["489-500"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6580847"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["46(2)"],"pubmed_abstract":["<h4>Purpose</h4>Metabolic imaging using [<sup>18</sup>F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously developed PET tracers based on the humanised anti-CD20 antibody obinutuzumab (GA101). Preclinical studies showed that the smallest bivalent fragment, the cys-diabody (GAcDb, 54.5 kDa) with a peak uptake at 1-2 h post-injection and a biological half-life of 2-5 h, is compatible with short-lived positron emitters such as fluorine-18 (<sup>18</sup>F, t<sub>1/2</sub> 110 min), enabling same-day imaging.<h4>Methods</h4>GAcDb was radiolabeled using amine-reactive N-succinimidyl 4-[<sup"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["<sup>18</sup>F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice."],"pmcid":["PMC6580847"],"funding_grant_id":["CA149254","P30 CA016042","R21 CA212718","CA212718","R01 CA149254","R01 CA174294","CA016042"],"pubmed_authors":["Wu AM","Tsai WK","Tavare R","Zettlitz KA","van Dam RM","Yamada RE","Timmerman JM","Ha NS","Collins J"],"additional_accession":[]},"is_claimable":false,"name":"<sup>18</sup>F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.","description":"<h4>Purpose</h4>Metabolic imaging using [<sup>18</sup>F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously developed PET tracers based on the humanised anti-CD20 antibody obinutuzumab (GA101). Preclinical studies showed that the smallest bivalent fragment, the cys-diabody (GAcDb, 54.5 kDa) with a peak uptake at 1-2 h post-injection and a biological half-life of 2-5 h, is compatible with short-lived positron emitters such as fluorine-18 (<sup>18</sup>F, t<sub>1/2</sub> 110 min), enabling same-day imaging.<h4>Methods</h4>GAcDb was radiolabeled using amine-reactive N-succinimidyl 4-[<sup","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Feb","modification":"2025-04-22T14:13:22.353Z","creation":"2020-10-29T11:02:32Z"},"accession":"S-EPMC6580847","cross_references":{"pubmed":["30456475"],"doi":["10.1007/s00259-018-4214-x"]}}